Novartis Seeks European Approval For Galvus
This article was originally published in The Pink Sheet Daily
Executive Summary
The novel type 2 diabetes therapy has a likely November user fee date in the U.S.
You may also be interested in...
Galvus Trial May Show Potential For Modifying Type 2 Diabetes Treatment Guidelines
Novartis initiates 7,500-patient head-to-head trial investigating the DPP-IV inhibitor compared to thiazolidinediones.
Galvus Trial May Show Potential For Modifying Type 2 Diabetes Treatment Guidelines
Novartis initiates 7,500-patient head-to-head trial investigating the DPP-IV inhibitor compared to thiazolidinediones.
Merck Research Appointment Reflects Firm's Emphasis On Diabetes, Obesity
Academic Rossetti will have responsibility over scientific direction of Merck's pipeline in the therapeutic areas as VP and franchise head.